用法用量 |
IVF(rate: initial dose over 60 minutes, if tolerated, may infuse subsequent doses over 30 minutes.)
Urothelial carcinoma, locally advanced or metastatic
840 mg once every 2 weeks or 1,200 mg once every 3 weeks or 1,680 mg once every 4 weeks; continue until disease progression or unacceptable toxicity.
Non-small cell lung cancer (NSCLC), metastatic
First-line treatment NSCLC (single agent): 840 mg once every 2 weeks or 1,200 mg once every 3 weeks or 1,680 mg once every 4 weeks; continue until disease progression or unacceptable toxicity.
First-line treatment, non-squamous NSCLC:
(1)1,200 mg on day 1 every 3 weeks (in combination with bevacizumab, paclitaxel, and carboplatin) for 4 to 6 cycles, followed by atezolizumab 1,200 mg on day 1 (followed by bevacizumab) every 3 weeks until disease progression or unacceptable toxicity; if bevacizumab is discontinued after the 4 to 6 cycles of combination chemotherapy, atezolizumab may be continued as a single agent at 840 mg once every 2 weeks or 1,200 mg once every 3 weeks or 1,680 mg once every 4 weeks until disease progression or unacceptable toxicity.
(2) 1,200 mg on day 1 every 3 weeks (in combination with paclitaxel [protein bound] and carboplatin) for 4 to 6 cycles ; after the 4 to 6 cycles of induction combination chemotherapy, atezolizumab may be continued as a single agent at 840 mg once every 2 weeks or 1,200 mg once every 3 weeks or 1,680 mg once every 4 weeks until disease progression or unacceptable toxicity.
Small cell lung cancer
Induction: 1,200 mg on day 1 every 3 weeks in combination with carboplatin and etoposide for 4 cycles, followed by maintenance therapy of single-agent atezolizumab at 840 mg once every 2 weeks or 1,200 mg once every 3 weeks or 1,680 mg once every 4 weeks; continue until disease progression or unacceptable toxicity.
Breast cancer (triple negative), locally advanced or metastatic
840 mg on days 1 and 15 every 4 weeks, followed by paclitaxel protein-bound 100 mg/m2 on days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
Hepatocellular carcinoma, unresectable or metastatic
1,200 mg once every 3 weeks, followed by bevacizumab 15 mg/kg IV on the same day, every 3 weeks until disease progression or unacceptable toxicity. |